** Shares of drugmaker BridgeBio Pharma BBIO.O rise 2.7% to $39.67
** Brokerage H.C. Wainwright raises PT to $56 from $53
** Believe BBIO's rare heart disease drug, acoramidis, could reach annualized revenue run rate of more than $1 billion in mid- to late 2027 in the U.S. — H.C. Wainwright
** Acoramidis reduced incidence of atrial fibrillation events in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), BBIO said in May
** Believe that this evidence, coupled with the growing proof that increased TTR stabilization extent is closely linked to favorable outcomes, should accelerate acoramidis market adoption — brokerage
** BBIO has fallen 8.3% YTD, as of last close
(Reporting by Juby Babu in Mexico City)
((Juby.Babu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.